← Russell 3000 cross-section

ATEC Alphatec Holdings, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-04, not restated
Healthcare

Scale

Market cap
$1.5bn
Revenue TTM
$815m
Net income TTM
$-110m
Free cash flow
$2m
Composite score
39.4
Sector rank
#1802

Valuation

P / E
EV / EBITDA
69.4
EV / sales
2.4
FCF yield
0.16%
Earnings yield vs 10-yr
-12.16pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-13.5%
EBITDA margin
3.4%
ROE
911.4%
ROIC
-11.1%
Revenue growth
19.5%

Insider activity, last 90 days

Net open-market
$-0.13m
Buyers
0
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

That adoption-driven validation has been the source of industry-leading market share expansion, which has delivered an approximately 35% revenue compound annual growth rate since our transformation commenced in 2018. To deliver consistent, predictable growth, we have added, and intend to continue to add, clinically astute and exclusive sales team members to reach untapped surgeons, hospitals, and national accounts and better penetrate existing accounts and territories. …Alphatec Holdings, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-04

Read the full passage →